Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer

Background The oncogenic receptor tyrosine kinase (RTK) ERBB2 is known to dimerize with other EGFR family members, particularly ERBB3, through which it potently activates PI3K signalling. Antibody-mediated inhibition of this ERBB2/ERBB3/PI3K axis has been a cornerstone of treatment for ERBB2-amplifi...

Full description

Saved in:

Bibliographic Details
Published in:	Breast cancer research : BCR Vol. 21; no. 1; pp. 43 - 17
Main Authors:	Kennedy, Sean P., Han, Jeremy Z. R., Portman, Neil, Nobis, Max, Hastings, Jordan F., Murphy, Kendelle J., Latham, Sharissa L., Cadell, Antonia L., Miladinovic, Dushan, Marriott, Gabriella R., O’Donnell, Yolande E. I., Shearer, Robert F., Williams, James T., Munoz, Amaya Garcia, Cox, Thomas R., Watkins, D. Neil, Saunders, Darren N., Timpson, Paul, Lim, Elgene, Kolch, Walter, Croucher, David R.
Format:	Journal Article
Language:	English
Published:	London BioMed Central 21.03.2019 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	1-Phosphatidylinositol 3-kinase Allosteric properties Animals Antibodies Antibodies, Monoclonal, Humanized - pharmacology Biomarkers Biomedical and Life Sciences Biomedicine Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer cells Cancer patients Cancer Research Cancer therapies Cell activation Cell culture Cell Line, Tumor Cell proliferation Chemotherapy Clinical trials Dimerization Disease Models, Animal Displays (Marketing) Dose-Response Relationship, Drug Drug Resistance, Neoplasm Drug therapy Enzyme inhibitors Epidermal growth factor Epidermal growth factor receptors ErbB-2 protein ErbB-3 protein ERBB2 Extracellular signal-regulated kinase Family relations Female Fluorescent Antibody Technique Heterodimers Humans Immunoglobulins Immunohistochemistry Immunotherapy Kinases Lapatinib Ligands Medical prognosis Metastasis Mice Monoclonal antibodies Oncology Patients Pertuzumab Phenols (Class of compounds) Phosphorylation Promiscuity Protein interaction Protein Kinase Inhibitors - pharmacology Protein Multimerization Protein-protein interactions Protein-tyrosine kinase receptors Receptor tyrosine kinases Receptor, ErbB-2 - antagonists & inhibitors Receptor, ErbB-2 - chemistry Receptor, ErbB-2 - metabolism Research Article Signal transduction Signal Transduction - drug effects Surgical Oncology Targeted cancer therapy Trastuzumab Trastuzumab - pharmacology Tumor cell lines Tyrosine Xenograft Model Antitumor Assays Xenografts United States > US Heterodimers Breast cancer Pertuzumab Receptor tyrosine kinases ERBB2
ISSN:	1465-542X, 1465-5411, 1465-542X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!